{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:04:05Z","timestamp":1762981445074,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU344"],"award-info":[{"award-number":["CRU344"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009398","name":"Medizinische Fakult\u00e4t, RWTH Aachen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.molmed.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T09:09:52Z","timestamp":1662109792000},"page":"902-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mast cells as a therapeutic target in myeloproliferative neoplasms"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-7381","authenticated-orcid":false,"given":"Marcelo A.S.","family":"Toledo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2022.08.008_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"M\u00e9ndez-Ferrer","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2022.08.008_bb0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/imr.12626","article-title":"The controversial role of mast cells in fibrosis","volume":"282","author":"Bradding","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molmed.2022.08.008_bb0015","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.08.008_bb0020","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","article-title":"Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders","volume":"113","author":"Ishii","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/leu.2009.85","article-title":"Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms","volume":"23","author":"Wang","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2022.08.008_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2020.102420","article-title":"Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms","volume":"82","author":"Keski","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.molmed.2022.08.008_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2021-151492","article-title":"IL13 contributes to fibrotic progression of the myeloproliferative neoplasms","volume":"138","author":"Melo-Cardenas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.08.008_bb0040","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood.2019004509","article-title":"Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis","volume":"137","author":"Toledo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2022.08.008_bb0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.08.008_bb0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.08.008_bb0055","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2\u2013 inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release","volume":"48","author":"Hermans","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.molmed.2022.08.008_bb0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/thoraxjnl-2019-214000","article-title":"Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects","volume":"75","author":"Overed-Sayer","year":"2020","journal-title":"Thorax"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:26:36Z","timestamp":1761463596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491422002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1471491422002131"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2022.08.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"type":"print","value":"1471-4914"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast cells as a therapeutic target in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}